• By Donald Zuhn —

    Federal Circuit SealLast week, in Neptune Generics, LLC v. Eli Lilly & Co., the Federal Circuit affirmed a determination by the U.S. Patent and Trademark Office Patent Trial and Appeal Board in an inter partes review that claims 1-22 of U.S. Patent No. 7,772,209 were not unpatentable for obviousness.  In affirming the Board's decision, the Federal Circuit found that the Board did not err in conducting its obviousness analysis and that substantial evidence supported the Board's factual findings.  The Federal Circuit also noted that the issue of subject matter eligibility was not properly before the Court.

    The '209 patent, which is owned by Eli Lilly & Co., is directed to methods of administering folic acid and a methylmalonic acid ("MMA") lowering agent, such as vitamin B12, before administering pemetrexed disodium, a chemotherapy agent, in order to reduce the toxic effects of pemetrexed, an antifolate.  Antifolates slow the ability of cells to divide by inhibiting enzymes that the cells use to make the components of DNA and RNA, but as a result, also have toxic effects that can be life threatening.  The two independent claims of the '209 patent recite:

    1.  A method for administering pemetrexed disodium to a patient in need thereof comprising administering an effective amount of folic acid and an effective amount of a methylmalonic acid lowering agent followed by administering an effective amount of pemetrexed disodium, wherein the methylmalonic acid lowering agent is selected from the group consisting of vitamin B12, hydroxycobalamin, cyano-10-chlorocobalamin, aquocobalamin perchlorate, aquo-10-cobalamin perchlorate, azidocobalamin, cobalamin, cyanocobalamin, or chlorocobalamin.

    12.  An improved method for administering pemetrexed disodium to a patient in need of chemotherapeutic treatment, wherein the improvement comprises:
        a)  administration of between about 350 μg and about 1000 μg of folic acid prior to the first administration of pemetrexed disodium;
        b)  administration of about 500 μg to about 1500 μg of vitamin B12, prior to the first administration of pemetrexed disodium; and
        c)  administration of pemetrexed disodium.

    Three petitions seeking inter partes review of the '209 patent were filed by Appellants Neptune Generics, LLC; Fresenius Kabi USA, LLC; and Mylan Laboratories Ltd.  The first petition asserted that claims 1–22 of the '209 patent are obvious in view of a 1999 article by Hilary Calvert, a 1998 abstract by Niyikiza et al. ("Niyikiza I"), a 1998 article by Worzalla et al., European Patent Application No. 0 595 005 A1 ("EP005"), and U.S. Patent No. 5,217,974.  The second petition asserted that the claims of the '209 patent are obvious in view of Niyikiza I, the '974 patent, and EP005.  The third petition asserted that the claims of the '209 patent are obvious over a 1999 article by Rusthoven et al. and EP005.  In the IPRs that were instituted, the Board concluded that the claims of the '209 patent were not established to be unpatentable for obviousness.  In particular, the Board concluded that while it was known in the art that pretreatment with folic acid reduces the toxicity associated with administration of an antifolate, like pemetrexed, there was no reason to also pretreat with vitamin B12 before administering pemetrexed to treat cancer.  The Board also found that the skepticism of others, particularly the FDA, supported a conclusion of nonobviousness.

    On appeal, Appellants focused on three references:  Niyikiza I, EP005, and another abstract by Niyikiza et al. ("Niyikiza II").  With respect to EP005, Appellants argued that the Board did not consider all that this reference teaches in finding that that the skilled artisan would not have been motivated to administer an MMA lowering agent, such as vitamin B12, in addition to folic acid.  In particular, Appellants argued that EP005 discloses administration of folic acid and vitamin B12 to lower homocysteine levels for all purposes.  The Federal Circuit, however, found that substantial evidence supported the Board's findings.  In particular, the Court determined that substantial evidence supported the Board's findings that elevated levels of homocysteine were known to be predictive of pemetrexed toxicity and elevated levels of MMA were understood not to be predictive of pemetrexed toxicity, that a skilled artisan would have understood that there was no observed correlation between vitamin B12 deficiency and pemetrexed-induced toxicity, and therefore, that the prior art did not provide a motivation for a skilled artisan to administer an MMA lowering agent, such as vitamin B12, in addition to folic acid.  With respect to EP005, the Federal Circuit pointed out that the Board had determined that this reference was concerned with the cardiovascular effects associated with elevated homocysteine levels, does not discuss antifolates generally, and only generally mentions certain cancers, explaining that "[g]iven the contrast between the specific, directly applicable teachings of Niyikiza II and the tangential, general statements of EP005, substantial evidence supports the Board's finding that EP005 did not provide information as to how pretreatment with folic acid and vitamin B12 would impact toxicity effects."

    Appellants also argued that the Board erred by not considering statements made by Lilly to the FDA concerning clinical trials of pemetrexed.  In particular, Appellants argued that Lilly had "inform[ed] the FDA that the prior art suggested that pretreating with folic acid and B12 was a no-risk, predictable way to lower pemetrexed-induced fatalities by lowering pretreatment homocysteine levels," and that Lilly's statements reflected the background knowledge of the skilled artisan and were indicators of the level of ordinary skill in the art.  In concluding that the Board did not err in declining to read the cited references in view of Lilly's statements to the FDA, the Federal Circuit noted that the statements were made more than five months after the critical date, and "[a]s the Board found, the views Lilly expressed about the prior art references in its communications are made through the lens of what they had invented."

    In finding that claims 1-22 of the '209 patent were not unpatentable for obviousness, the Board determined that the evidence of skepticism of others, particularly the FDA, supported a conclusion of nonobviousness.  During clinical trials for pemetrexed, in which a number of fatalities had occurred, Lilly recommended to the FDA that pemetrexed administration be supplemented with folic acid and vitamin B12, and the FDA responded that it did not support adding vitamins to the ongoing trial because the addition of vitamins was "risky."  Appellants argued that the Board erred in finding this evidence to be sufficient to support a finding of skepticism because the FDA allowed the trial to continue, and skepticism must be premised on whether it is "technically infeasible," "unworkable," or "impossible" that the claimed subject matter would work for its intended purpose.  The Federal Circuit, however, disagreed with Appellants, stating that their "position is not consistent with our caselaw, which recognizes a range of third-party opinion that can constitute skepticism," and finding that "[w]hile evidence that third parties thought the invention was impossible might be entitled to more weight, that does not mean the Board erred in giving weight to the skepticism evidence here."  The Federal Circuit therefore determined that the Board did not err in finding that skepticism supported a conclusion of nonobviousness.

    Finally, with respect to Appellants' argument that the claims are not directed to patentable subject matter (asserting that the issue was properly raised because eligibility is a question of law and that there were no factual issues that must be decided in the appeal), the Federal Circuit noted that the ground of patent eligibility arises under § 101, and therefore, that the Court was precluded from addressing the issue on appeal of an IPR.  The Federal Circuit therefore affirmed the Board's determination that claims 1-22 of the '209 patent were not unpatentable for obviousness.

    Neptune Generics, LLC v. Eli Lilly & Co. (Fed. Cir. 2019)
    Panel: Circuit Judges Moore, Wallach, and Hughes
    Opinion by Circuit Judge Moore

  • By Kevin E. Noonan —

    U.S. Trade RepresentativeOn April 25th, Ambassador Robert Lighthizer, U.S. Trade Representative (USTR), issued the 2019 Special 301 Report.  In a press release, the USTR stated that "over the coming weeks, USTR will review the developments against the benchmarks established in the Special 301 action plans for countries that have been on the Priority Watch List for multiple years," and that for those countries found not to have addressed the concerns expressed by and attendant to placement on these lists, "USTR will take appropriate actions, such as enforcement actions under Section 301 of the Trade Act or pursuant to World Trade Organization or other trade agreement dispute settlement procedures, necessary to combat unfair trade practices and to ensure that trading partners follow through with their international commitments."

    According to the Executive Summary of the Report, "[a] top trade priority for the Administration is to use all possible sources of leverage to encourage other countries to open their markets to U.S. exports of goods and services, and provide adequate and effective protection and enforcement of U.S. intellectual property (IP) rights."  In tune with the more combative rhetoric on trade adopted by the Trump Administration, the Summary goes on to add that:

    This Report provides an opportunity to call out foreign countries and expose the laws, policies, and practices that fail to provide adequate and effective IP protection and enforcement for U.S. inventors, creators, brands, manufacturers, and service providers.  The identification of the countries and IP-related market access barriers in the Report and of steps necessary to address those barriers are a critical component of the Administration's aggressive efforts to defend Americans from harmful IP-related trade barriers.

    The Report cites four countries for particular consideration upon being placed on the Priority Watch List.  Regarding China, the Report characterizes placement on the list because in the Administration's view China needs "fundamental structural changes to strengthen IP protection and enforcement, including as to trade secret theft, online piracy and counterfeiting, the high-volume manufacture and export of counterfeit goods, and impediments to pharmaceutical innovation."  India is cited for "lack of sufficient measurable improvements to its IP framework on long-standing and new challenges that have negatively affected U.S. right holders over the past year," which include ones that "make it difficult for innovators to receive and maintain patents in India, particularly for pharmaceuticals, insufficient enforcement actions, copyright policies that do not properly incentivize the creation and commercialization of content, and an outdated and insufficient trade secrets legal framework."  Saudi Arabia was moved from the Watch List to the Priority Watch List this year, according to the Report, "for failing to address longstanding IP concerns and further deteriorating IP protection and enforcement within its borders" and specifically cites, "lack of IP protection for innovative pharmaceutical products, including the lack of adequate and effective protection against unfair commercial use, as well as unauthorized disclosure, of undisclosed test or other data generated to obtain marketing approval" and "rampant satellite and online piracy made available by illicit pirate service BeoutQ."  The Report highlights the deficiencies of Indonesia as a trading partner less particularly, merely citing a "reported lack of adequate and effective IP protection and enforcement" (presumably from comments received from particular constituencies who have done the "reporting" to the Administration).

    The Report is promulgated pursuant to Section 182 of the Trade Act of 1974, as amended by the Omnibus Trade and Competitiveness Act of 1988 and the Uruguay Round Agreements Act (enacted in 1994).  The Trade Representative is required under the Act to "identify those countries that deny adequate and effective protection for IPR or deny fair and equitable market access for persons that rely on intellectual property protection."  The Trade Representative has implemented these provisions by creating a "Priority Watch List" and "Watch List."  Placing a country on the Priority Watch List or Watch List is used to indicate that the country exhibits "particular problems . . . with respect to IPR protection, enforcement, or market access for persons relying on intellectual property."  These watch lists are reserved for countries having "the most onerous or egregious acts, policies, or practices and whose acts, policies, or practices have the greatest adverse impact (actual or potential) on the relevant U.S. products."

    The USTR reviewed "more than 100" of this country's trading partners and identified eleven countries on a "Priority Watch List" (increased by one from last year) and another 25 countries on the "Watch List" (also increasing by one from last year), all relating to deficiencies in intellectual property protection in these countries.  The Priority Watch List in the 2019 Report includes Algeria, Argentina, Chile, China, India, Indonesia, Kuwait, Russia, Saudi Arabia, Ukraine, and Venezuela, and removes Canada and Thailand from the list cited in the 2018 Report.  Countries on this list "present the most significant concerns this year regarding insufficient IP protection or enforcement or actions that otherwise limited market access for persons relying on intellectual property protection."  On the Watch List this year are Barbados, Bolivia, Brazil, Canada, Columbia, Costa Rica, Dominican Republic, Ecuador, Egypt, Greece, Guatemala, Jamaica, Lebanon, Mexico, Pakistan, Paraguay, Peru, Romania, Switzerland, Thailand, Turkey, Turkmenistan, United Arab Emirates, Uzbekistan, and Vietnam.  Canada, Thailand, and the United Arab Emirates were added, and Saudi Arabia was moved to the Priority Watch List this year.

    The Report also notes the USTR's continued efforts to enhance public engagement.  In addition to written comments (from 73 interested parties, including 25 trading partner governments), there was a public hearing on February 27, 2019 that heard testimony from "representatives of foreign governments, industry, and non-governmental organizations" (where the comments and a transcript and video of the hearing are available on the USTR website).

    The Report states that "[i]n virtually all countries identified in this Report, IP enforcement is lacking," due to, inter alia, "[in]adequate or effective border enforcement against counterfeit and pirated goods" (Brazil, China, Colombia, Hong Kong, India, Indonesia, Nigeria, Paraguay, Singapore, Thailand, Turkey, the UAE, and Vietnam), and that in such countries "customs officials lack authority to take ex officio action to seize and destroy such goods at the border or to take such action for goods in-transit."

    Particularly mentioned are copyright issues, including piracy (Argentina, Bulgaria, Canada, Chile, China, Colombia, Greece, India, Mexico, the Netherlands, Romania, Russia, Saudi Arabia, Switzerland, Ukraine, "and elsewhere") and unlicensed government use of copyrighted software (Argentina, Brazil, China, Costa Rica, Egypt, Greece, Indonesia, Kenya, Mexico, Nigeria, the Philippines, Romania, Russia, Thailand, and Vietnam).

    The Report also cites "restrictive patentability criteria" (Argentina, India, and Indonesia) and "a lack of effective protection against unfair commercial use, as well as unauthorized disclosure, of test or other data generated to obtain marketing approval for pharmaceutical and agricultural chemical products" (Argentina, China, India, and Saudi Arabia).

    As it did last year, the Report also chides India and China for inadequate trade secret protection, which puts "U.S. trade secrets at unnecessary risk" and "negative market access effects" from the European Union's geographical indications (GIs) protections.

    Somewhat paradoxically, this portion of the Report ends by stating that "the Office of the U.S. Trade Representative looks forward to working closely with the trading partners identified in this year's Report to address these and other priority concerns."

    Results of 2018 "Out of Cycle" reviews discussed in the Report (which "provide an opportunity to address and remedy such issues through heightened engagement and cooperation with trading partners and other stakeholders") include Columbia, which "made meaningful progress in enacting copyright reform legislation to meet CTPA obligations and is actively engaging stakeholders on Internet service provider (ISP) liability to address another CTPA commitment."  Kuwait did not fare so well, the USTR determining that while this country has "made some progress," the issue that prompted the review "had not been resolved."  For Malaysia, despite "numerous consultations with a view to resolving outstanding issues," the USTR has decided to extend review in 2019, in order to "consider the extent to which Malaysia is providing adequate and effective IP protection and enforcement, including with respect to patents."

    The Report contains two Sections (on "Developments in Intellectual Property Rights Protection and Enforcement" and "Country Reports") and two Annexes on particular issues (the statutory bases of the Report, and government technical assistance and capacity building efforts).  In Section I, the Report reiterates its raison d'etre, that:

    Intellectual property (IP) infringement, including patent infringement, trademark counterfeiting, copyright piracy, and trade secret theft, causes significant financial losses for right holders and legitimate businesses around the world.  IP infringement undermines U.S. competitive advantages in innovation and creativity, to the detriment of American businesses and workers.  In its most pernicious forms, IP infringement endangers the public, such as through exposure to health and safety risks from counterfeit products such as semiconductors, automobile parts, apparel, footwear, toys, and medicines.  In addition, trade in counterfeit and pirated products often fuels cross-border organized criminal networks and hinders sustainable economic development in many countries.  Fostering innovation and creativity is essential to U.S. economic growth, competitiveness, and the estimated 45 million American jobs that directly or indirectly rely on IP-intensive industries.  USTR continues to work to protect American innovation and creativity in foreign markets employing all the tools of U.S. trade policy, including the annual Special 301 Report.

    It then reviews "initiatives for strengthen IP protection and enforcement," which includes "examples of initiatives to strengthen IP protection and enforcement; illustrative best practices demonstrated by the United States and our trading partners; [and] U.S.-led initiatives in multilateral organizations; and bilateral and regional developments."  It also highlights areas of continued concern, including "counterfeits, online piracy, forced technology transfer, innovative pharmaceutical products and medical devices, and geographical indications (GIs)."  As in earlier years, it mentions how important IP protection is to innovations in the environmental sector.  Finally, Section I includes a discussion relating to "the importance of full implementation of the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) and developments on the U.S. use of WTO dispute settlement procedures to resolve IP concerns."

    In a section entitled "IP Protection and Enforcement and Related Market Access Challenges," the Report discusses innovation in the pharmaceutical industry, medical devices and market access concerns.  In this regard, the Report states that "USTR has been engaging with trading partners to ensure that U.S. owners of IP have a full and fair opportunity to use and profit from their IP, including by promoting transparent and fair pricing and reimbursement systems."  These efforts have included "ensur[ing] robust IP systems; reduc[ing] market access barriers to pharmaceutical products and medical devices, including measures that discriminate against U.S. companies, are not adequately transparent, or do not offer sufficient opportunity for meaningful stakeholder engagement; and has pressed trading partners to appropriately recognize the value of innovative medicines and medical devices so that trading partners contribute their fair share to research and development of new treatments and cures" (echoing the "fair share" mantra recited by the President in stump speeches and tweets).  The Report calls out in this regard the following efforts in particular countries:

    • Canada and Mexico: in the context of renegotiating the North American Free Trade Agreement (NAFTA), secured strong IP provisions in the United States-Mexico-Canada Agreement (USMCA), including provisions that "ensure that national-level government processes for the listing and reimbursement of pharmaceutical products and medical devices are transparent, provide procedural fairness, are nondiscriminatory, and provide full market access for U.S. products";

    • Korea: as part of renegotiating the U.S.-Korea Free Trade Agreement (KORUS FTA), obtained a commitment to "amend its Premium Pricing Policy for Global Innovative Drugs" to "ensure fair and non-discriminatory treatment of pharmaceutical products";

    • Japan: engaged "to ensure transparency and fairness and address other concerns with respect to pharmaceutical and medical devices pricing and reimbursement policies";

    • China: "pressed" the Chinese on "a range of issues affecting the pharmaceutical sector, including on the need to implement an effective mechanism for the early resolution of potential patent disputes; provide effective protection against unfair commercial use, as well as unauthorized disclosure, of test or other data generated to obtain marketing approval for pharmaceutical products; and provide a reliable and effective means of extending the patent term to compensate for the marketing approval review period and for patent office delays";

    • India: engaged to secure "meaningful IP reforms on longstanding issues," which include patentability and compulsory licensing criteria, protection against unfair commercial use and unauthorized disclosure of test or other data generated to obtain marketing approval for pharmaceutical products;

    • Indonesia: "pressed" to resolve concerns regarding Indonesian patent law, including patentability criteria, compulsory licensing, and requirements for local manufacturing and use;

    • Argentina: "raised concerns" regarding (somewhat ironically) the scope of patentable subject matter, protection against unfair commercial use and, like in many emerging countries, unauthorized disclosure of "undisclosed test or other data generated to obtain marketing approval for pharmaceutical and agricultural chemical products";

    • Saudi Arabia: "engaged" (in view of transfer to the Priority Watch List, apparently somewhat unsuccessfully) regarding patent enforcement and protections against unfair commercial use, and also unauthorized disclosure of "undisclosed test or other data generated to obtain marketing approval for pharmaceutical products"; and

    • United Arab Emirates (UAE): sought (but did not receive?) confirmation that UAE will provide protection for pharmaceuticals through, inter alia, the Gulf Cooperation Council (GCC) patent system.

    Compulsory licensing again poses particular concerns with regard to pharmaceuticals and medical devices, according to the Report, because "[s]uch actions can undermine a patent holder's IP, reduce incentives to invest in research and development for new treatments and cures, unfairly shift the burden for funding such research and development to American patients and those in other markets that properly respect IP, and discourage the introduction of important new medicines into affected markets."  Even when compulsory licenses are justified they should be used in only "extremely limited circumstances" and only after attempting to negotiate with the rights holder; the Report cited these concerns particularly with Chile, Colombia, El Salvador, India, Indonesia, Malaysia, Russia, Turkey and Ukraine.

    More generally, the Report points to "non-transparent" and discriminatory practices and "unreasonable regulatory delay" as being of concern to the USTR and administration.  In contrast, national systems that accelerate approval based on regulatory in other countries are praised in the Report.

    The Report notes that stakeholders from the pharmaceutical and medical device industries have identified industries that have expressed concerns regarding the policies of several trading partners, including Algeria, Australia, Canada, China, Japan, Korea, New Zealand, and Turkey with regard to "issues related to pharmaceutical innovation and market access," citing specific examples falling within these general categories for each country.

    The Report next turns to technology transfer issues, including innovation by indigenous peoples and "localization."  In this portion of the Report, compulsory technology transfer is emphasized as causing difficulties for American innovators.  The Report identifies the anti-innovation cycle of imposing such measures to incentivize local innovation, which leads to create market entry barriers and thus discourages foreign (i.e., U.S.) investment, which not only hurts domestic industry in those countries but also can produce "non-market distortions" which in turn can lead to "suboptimal outcomes."  The Report sets forth a litany of these practices, including requirements for technology transfer as the price for regulatory or other governmental approval; permitting state-owned enterprises to seek "non-commercial terms" for IP licensing or otherwise; providing unfair competitive advantage to local industry (if only passively by permitting U.S. IP-rights infringement); permitting cyber-intrusions; giving preference to local products and services dependent on indigenous IP; "[m]anipulating" processes of standards to prefer local concerns; and conditioning regulatory approval or other governmental approvals on disclosure of confidential business information and then "failing to protect such information appropriately."  China, Indonesia, Nigeria, and Turkey are particularly cited for these concerns.

    Trade secret protection, or lack of it, is also a concern discussed in the Report.  It cites "growing need for trading partners to provide effective protection and enforcement of trade secrets" in "a wide variety of industry sectors, including 'ICT' [information and communications technologies], services, pharmaceuticals and medical devices, environmental technologies, and other manufacturing" areas.  The Report cites "various sources, including the U.S. Office of the National Counterintelligence Executive" for reporting these concerns, particularly with regard to China.  Trade secret theft can arise in "a variety of circumstances," including permitting (or not stopping) departing employees from taking with them trade secret information-containing electronic storage devices, failed joint ventures, cyber intrusion and computer hacking, misuse of trade secrets disclosed to government agencies as part of a regulatory approval process.  The Report notes particular difficulties in China and India regarding "effective remedies," or that (in some countries) government regulations or policies require disclosure of trade secrets such as software source code.  While asserting that "[t]he United States uses all trade tools available to ensure that its trading partners provide robust protection for trade secrets and enforce trade secrets laws," the Report cites on a positive note efforts by the European Union and Taiwan to strengthen their trade secret regimes. The USTR also "strongly supports" the work of the Organization for Economic Cooperation and Development (OECD)'s work on trade secret protection.

    The Report next addresses geographical indications (GIs) issues, saying that the U.S. "is working intensively through bilateral and multilateral channels" to improve U.S. access to a variety of goods having geographic specificity, particularly with regard to the European Union.  The EU GI "agenda remains highly concerning, because it significantly undermines the scope of trademarks and other IP rights held by U.S. producers and imposes barriers on market access for American-made goods that rely on the use of common names, such as parmesan or feta."  As a result, according to the Report, there are concerns "regarding the extent to which it impairs the scope of trademark protection," which (answering its own question) the Report states "undermines trademark protection and may result in consumer confusion to the extent that it permits the registration of GIs that are confusingly similar with prior trademarks."  The Report exemplifies these concerns regarding GI protection granted by the EU for a cheese called danbo, which the USTR states is made in many other countries but use of this name is restricted in the EU to particular (European) geographic source.  The Report asserts without characterization that the EU "pressures trading partners to prevent all producers, other than in certain EU regions, from using certain product names" (all of which relate to cheese, curiously), with as a consequence "American producers and traders either are effectively blocked from those markets or must adopt burdensome workarounds" (illustrated, unfortunately for the strength of the argument, by appending "-like" to the particular cheese name).  Part of the reason for U.S. concern is frankly admitted to be that "[t]he United States runs a significant deficit in food and agricultural trade with the EU," comparing $1 billion in cheese exports from the EU to the U.S. with $5 million in imports into the EU from the U.S.  More worrisome is the EU's extension of GI designations into other goods, including "non-agricultural products, including apparel, ceramics, glass, handicrafts, manufactured goods, minerals, salts, stones, and textiles."  Despite urging from the U.S., the EU amended its Common Agricultural Policy to pass much of the control over GIs to "interested EU Member States" (i.e., those in the protected geographical location) with an attendant "sharp[]" reduction in the period available to oppose a GI designation.  The Report also notes that the EU is pursuing its GI agenda in "multilateral and plurilateral bodies," including "expanding the World Intellectual Property Organization (WIPO) Lisbon Agreement for the Protection of Appellations of Origin and their International Registration to include GIs, thereby enshrining several detrimental aspects of EU law in that Agreement."  The Report characterizes these efforts as a "break with the long-standing WIPO practice of consensus-based decision-making" and consequently voted to "deny the United States and 160 other WIPO countries meaningful participation rights in the negotiations."

    The Report also notes that the U.S. response is to address the issue in so-called "free trade" agreements and bilateral agreements with other nations, including Argentina, Brazil, Canada, Chile, China, Colombia, Ecuador, Indonesia, Japan, Malaysia, Mexico, Morocco, Paraguay, the Philippines, Singapore, South Africa, Tunisia, Uruguay, and Vietnam.

    The Report next turns to online and broadcast piracy of copyrighted works, citing the "increased availability of broadband Internet connections around the world" as being a "boon" to the U.S economy and foreign trade.  But while advances in technology have enabled U.S. creative producers to better distribute copyrighted materials, it has also made the Internet "an extremely efficient vehicle for disseminating infringing content, thus competing unfairly with legitimate e-commerce and distribution services that copyright holders and online platforms use to deliver licensed content."  A variety of forms of this issue are discussed in the Report, which names China, India, Indonesia Mexico, Peru, Ukraine, and Vietnam for optical piracy; Canada, Mexico, the Netherlands, Saudi Arabia, Sweden, and Switzerland for "stream-ripping" (which is "the unauthorized converting of a file from a licensed streaming site into an unauthorized copy" and is now a "dominant" method for music piracy); and Argentina, Brazil, Chile, China, the Dominican Republic, Hong Kong, India, Indonesia, Mexico, Peru, Saudi Arabia, Singapore, Taiwan, the UAE, and Vietnam for the use of illicit streaming devices.  Also mentioned (without attribution to any particular country) is illegal Internet Protocol Television and signal theft by cable operators as significant sources of copyright.  Illicit camcording continues to be a particular concern in the Report, which asserts that "online piracy that damage legitimate trade are found in virtually every country listed in the Special 301 Report and include: the unauthorized retransmission of live sports programming online; the unauthorized cloning of cloud-based entertainment software, through reverse engineering or hacking, onto servers that allow users to play pirated content online, including pirated online games; and online distribution of software and devices that allow for the circumvention of technological protection measures (TPMs), including game copiers and mod chips that allow users to play pirated games on physical consoles."

    The final extensive discussion in the Report regards border control and criminal enforcement against counterfeiting.  Counterfeit goods (including "semiconductors and other electronics, chemicals, automotive and aircraft parts, medicines, food and beverages, household consumer products, personal care products, apparel and footwear, toys, and sporting goods") "make their way from China" and other countries, particularly those having an "ineffective or inadequate IP enforcement system."  Citing a March 2019 OECD study entitled "Trends in Trade in Counterfeit and Pirated Goods," the cost of such counterfeiting was $509 billion in 2016, which is equivalent to 3.3% of 2016 total global trade n(with China accounting for 57%, $239 billion, of that trade). The Report states that such counterfeit goods harm "consumers, legitimate producers, and governments," particularly with regard to medicines, automotive and airplane parts, and food and beverages" because the counterfeit products do not meet the "rigorous good manufacturing practices used for legitimate products."  The Report enunciates difficulties that arise due to the use of legitimate sources of trade ("legitimate express mail, international courier, and postal services") for transporting counterfeit goods in small consignments or shop unmarked goods to which a counterfeit trademark are affixed at their final destination.  These practices inhibit trademark enforcement efforts, particularly in countries that require a counterfeit to be "completed" at the time of importation and inspection at national borders.  The Report states that the U.S. continues to "urge" its trading partners to "undertake more effective criminal and border enforcement against the manufacture, import, export, transit, and distribution of counterfeit goods" and states that the Office engages trading partners bilaterally, through trade agreement and international organizations on this issue.  Another problem is the reentry into channels of commerce of counterfeit goods after they have been seized at national borders and transshipment through 'free trade zones"; the Report uses the UAE, particularly Dubai, as an example of this practice that accounted for $16 billion in counterfeit goods in 2016.  Particular instances of trade in counterfeit medicines and global patterns of such drugs (e.g., India being a major supplier of counterfeit drugs to African countries) are also discussed in the Report.

    Copyright administration and royalty payments, particularly with regard to collective management organizations (BMI, ASCAP) are next discussed, with concern arising that "CMO systems in several countries are reportedly flawed or nonoperational," citing India, the UAE, and Ukraine as examples.

    Trademarks and impediments to obtaining and enforcing them in some countries make up the next topic in the Report, with Brazil, China, India, Malaysia, and the Philippines, having "slow" opposition proceedings and Russia and Panama having no administrative opposition proceedings.  Even registering (i.e., making a record of) trademarks is problematic in some countries, with "unnecessary administrative and financial burdens" imposed on owners and there being unnecessary difficulties in maintaining and enforcing trademarks (albeit without naming any countries where these and other difficulties contained in the Report have arisen).  There are also issues with cybersquatting and particularly with country code top-level domain names (ccTLDs) for U.S. rights holders.  The governments of Argentina, Brazil, Chile, China, Costa Rica, Egypt, Greece, Indonesia, Kenya, Mexico, Nigeria, the Philippines, Romania, Russia, Thailand, Ukraine, and Vietnam are named for unlicensed use of software, and the Report cites a commercial value for such illicit use of software at $46 billion worldwide.

    The Report sets forth efforts related to initiatives for improving IP protection resulting in a country not being put on the Watch List (Tajikistan), or other significant steps (in Brazil, Chile, Columbia, Costa Rica, Greece, India, the Philippines, and Taiwan).  Also noted is participation by 75 member states in the 1991 Act of the International Union for the Protection of New Varieties of Plants Convention (UPOV 91), which member states to "grant IP protection to breeders of new plant varieties, known as breeder's rights."  The Report asserts that "[a]n effective plant variety protection system incentivizes plant-breeding activities, which leads to increased numbers of new plant varieties with improved characteristics such as high-yield, tolerance to adverse environmental conditions, and better food quality."  Also noted are the 100 parties to each of the WIPO Performances and Phonograms Treaty and the WIPO Copyright Treaty, which have "raised the standard of copyright protection around the world, particularly with regard to online delivery of copyrighted content."

    Section I of the Report also has a section of "Illustrative Best IP Practices by [U.S.] Trading Partners, which expressly recites Thailand and India for "[c]ooperation and coordination among national government agencies involved in IP issues"; Brazil, Malaysia, and Jamaica for "[s]pecialized IP enforcement units"; India, Paraguay, the Philippines, Spain, and Taiwan for "IP awareness and educational campaigns"; and several governments (Mexico, Romania, Singapore) for active participation of government officials in technical assistance and capacity building."

    The Report discusses multilateral (WTO) and regional (APEC) and bilateral (TIFA) agreements and specific instances where such agreements are being pursued in furtherance of U.S. trade objectives.

    Section I of the Report ends by mentioning the role of intellectual property and the environment and intellectual property and health as areas of concern raised by stakeholders in their comments.  The Report contains an affirmation of the provisions regarding IP and public health set forth in the Doha Declaration and states that "[t]he United States is firmly of the view that international obligations such as those in the TRIPS Agreement have sufficient flexibility to allow trading partners to address the serious public health problems that they may face."  And the final portion of this section of the Report discusses efforts at dispute resolution of IP matters under the GATT/TRIPS provisions as they are implemented by the WTO.

    Finally, the last portion of Section I of the Report relates to dispute settlement and enforcement.  It states that while the U.S. believes that "[t]he most efficient and preferred manner of resolving concerns is through bilateral dialogue," when that doesn't work "the United States will use enforcement tools including those provided under U.S. law, the WTO and other dispute settlement procedures, as appropriate."  Specifically cited is the August 14, 2017 Presidential Memorandum regarding an investigation by the USTR of "laws, policies, practices, or actions of the government of China that may be unreasonable or discriminatory and that may be harming American intellectual property rights, innovation, or technology development" (82 FR 39007) and its subsequent institution on August 18, 2017.  The Report notes that the investigation reported, in March 22, 2018, that "the investigation supports findings that acts, policies, and practices of the China related to technology transfer, intellectual property, and innovation covered in the investigation are unreasonable or discriminatory and burden or restrict U.S. commerce" and the subsequent actions of the Administration to impose tariffs on Chinese goods and WTO involvement in "market access and distribution for imported publications, movies, music, and audio-visual home entertainment products, such as DVDs and Blu-ray discs (AVHE products)."  Other enforcement actions, mostly of historical significance, are also discussed.

    Section II of the Report is a detailed, country-by-country discussion for each country on the Priority Watch List and the Watch List, relating to the activities (or lack thereof) of each country that results in placement of that country on these lists.

    As it has for the past several years (and across otherwise very different Administrations), the U.S. Trade Representative Special 301 Report provides insights into both the concerns of U.S. IP rights holders and the Administration's intentions to work with, cajole, coerce, or threaten other countries to increase protection for IP rights of U.S. IP rights holders.  For anyone paying adequate attention to these Reports year-to-year, the complaints, and even the language enunciating these complaints, remains dispiritingly the same, suggesting that despite pronouncements of small victories efforts to reduce unfair trade practices globally have fallen far short.  Nevertheless, as with last year's Report, the tone and tenor of this Report is robustly assertive regarding IP rights and America's intention to negotiate international agreements and confront its trading partners in ways that protect American innovation and commercial interests first and foremost regardless of consequences.

    For additional information regarding this and other related topics, please see:

    • "U.S. Trade Representative Releases 2018 Special 301 Report," April 29, 2018
    • "U.S. Trade Representative Issues 2017 Special 301 Report," May 4, 2017
    • "U.S. Trade Representative Issues 2016 Special 301 Report," May 19, 2016
    • "U.S. Trade Representative Issues 2015 Special 301 Report," April 30, 2015
    • "U.S. Trade Representative Issues 2014 Special 301 Report," May 19, 2014
    • "U.S. Trade Representative Issues 2013 Special 301 Report," May 30, 2013
    • "U.S. Trade Representative Issues 2012 Special 301 Report," May 1, 2012
    • "U.S. Trade Representative Releases Special 301 Report on Global IPR," May 4, 2011
    • "U.S. Trade Representative Releases Special 301 Report on Global IPR," May 19, 2010
    • "New Administration, Same Result: U.S. Trade Representative's Section 301 Report," May 6, 2009
    • "Congressmen Criticize U.S. Trade Representative over Special 301 Report," July 1, 2008
    • "U.S. Continues Efforts to Protect Patent Rights Abroad," April 29, 2008

  • By Kevin E. Noonan —

    University of California-BerkleyLast Tuesday, the U.S. Patent and Trademark Office granted (at long last) to the University of California/Berkeley, the University of Vienna, and inventor Emmanuelle Charpentier a patent corresponding to the application-in-interference with the Broad's patent estate, as U.S. Patent No. 10,266,850, to its CRISPR technology (where CRISPR is an acronym for Clustered Regularly lnterspaced Short Palindromic Repeats).  The interference between the Broad Institute and the University of California/Berkeley over patents directed to CRISPR technology has been in the spotlight over the past few years (see "CRISPR Interference Declared"; "PTAB Decides CRISPR Interference — No interference-in-fact"; "PTAB Decides CRISPR Interference in Favor of Broad Institute — Their Reasoning"; "University of California/Berkeley Appeals Adverse CRISPR Decision by PTAB"; and "Berkeley Files Opening Brief in CRISPR Appeal"); the claims granted in the '850 patent correspond to those patentably distinct from the Broad's claims.

    The claims issued to Berkeley et al. as U.S. Patent No. 10,266,850 include the following:

    1.  A method of cleaving a nucleic acid comprising contacting a target DNA molecule having a target sequence with an engineered and/or non-naturally-occurring Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising a) a Cas9 protein; and b) a single molecule DNA-targeting RNA comprising i) a targeter-RNA that hybridizes with the target sequence, and ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment, wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides, wherein the single molecule DNA-targeting RNA forms a complex with the Cas9 protein, whereby the single molecule DNA-targeting RNA targets the target sequence, and the Cas9 protein cleaves the target DNA molecule.

    2.  An engineered and/or non-naturally-occurring Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising a Cas9 protein or a nucleic acid comprising a nucleotide sequence encoding the Cas9 protein, and a single molecule DNA-targeting RNA or a nucleic acid comprising a nucleotide sequence encoding the single molecule DNA-targeting RNA; wherein the single molecule DNA-targeting RNA comprises i) a targeter-RNA that is capable of hybridizing with a target sequence in a target DNA molecule, and ii) an activator-RNA that is capable of hybridizing with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment, wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides, and wherein the single molecule DNA-targeting RNA is capable of forming a complex with the Cas9 protein, whereby hybridization of the targeter-RNA to the target sequence is capable of targeting the Cas9 protein to the target DNA molecule.

    4.  A method of cleaving or editing a target DNA molecule or modulating transcription of at least one gene encoded thereon, the method comprising contacting a target DNA molecule having a target sequence with an engineered and/or non-naturally-occurring Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising: a) a single molecule DNA-targeting RNA comprising i) a targeter-RNA that hybridizes with the target sequence, and ii) an activator-RNA that hybridizes with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment, wherein the targeter-RNA and the activator-RNA are covalently linked to one another with intervening nucleotides; and b) a Cas9 protein, wherein the single molecule DNA-targeting RNA forms a complex with the Cas9 protein, thereby targeting the Cas9 protein to the target DNA molecule, whereby said target DNA molecule is cleaved or edited or transcription of at least one gene encoded by the target DNA molecule is modulated.

    40.  An engineered and/or non-naturally occurring Type II Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR associated (Cas) (CRISPR-Cas) system comprising a) a Cas9 protein, or a nucleic acid comprising a nucleotide sequence encoding said Cas9 protein; and b) a single molecule DNA-targeting RNA, or a nucleic acid comprising a nucleotide sequence encoding said single molecule DNA-targeting RNA; wherein the single molecule DNA-targeting RNA comprises: i) a targeter-RNA that is capable of hybridizing with a target sequence in a target DNA molecule, and ii) an activator-RNA that is capable of hybridizing with the targeter-RNA to form a double-stranded RNA duplex of a protein-binding segment, wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides; and wherein the single molecule DNA-targeting RNA is capable of forming a complex with the Cas9 protein, thereby targeting the Cas9 protein to the target DNA molecule, whereby said system is capable of cleaving or editing the target DNA molecule or modulating transcription of at least one gene encoded by the target DNA molecule.

    Berkeley, Vienna, and Charpentier have had three previous patents granted in its CRISPR portfolio (see "Whither CRISPR? University of California/Berkeley Granted Another CRISPR Patent" for a summary of the previously granted patents).  Like the other granted patents, the newly issued '850 patent claims are not limited to the type of cell in which the CRISPR reaction occurs (nor, indeed, are limited to any cell at all).  The subject matter eligibility of the claimed RNA molecules is presumably supported by limitations to "non-naturally occurring" (reminiscent of limiting transgenic animals to "non-human" embodiments) as well as by including the limitation "wherein the activator-RNA and the targeter-RNA are covalently linked to one another with intervening nucleotides," rendering them altered from how they are found in nature.

    While the Broad was successful in getting the Federal Circuit to affirm the PTAB's decision that there was no interference-in-fact between the parties' claims (see "Regents of the University of California v. Broad Institute, Inc. (Fed. Cir. 2018): Federal Circuit Affirms PTAB in Appeal of CRISPR Interference") and there have been reports of the outcomes of other skirmishes between the parties in the meantime (see "The CRISPR Chronicles — Broad Institute Wins One and Loses One"), questions remain about how the rights to this technology will be apportioned between the parties, and how useful, reliable patent licenses will be granted to permit robust development and fulfillment of the many promises of CRISPR in a wide variety of genetic contexts.  The patent situation remains somewhat murky, at least with regard to which entity, or both, or another, will ultimately have sufficiently strong or comprehensive patent protection to give licensees confidence in their rights to develop CRISPR technology to fulfill its great promise.

  • CalendarApril 29, 2019 – USPTO World Intellectual Property Day Celebration (U.S. Patent and Trademark Office, World Intellectual Property Organization, American Intellectual Property Law Association, U.S. Chamber of Commerce Global IP Center, International Trademark Association, American Bar Association's Section on Intellectual Property Law, and Intellectual Property Owners Association) – 4:00 to 6:30 pm, Rayburn House Office Building Foyer, Washington, DC

    April 30, 2019 – Customer partnership meeting of TC 3600 and TC 3700 (U.S. Patent and Trademark Office and American Intellectual Property Law Association) – 8:45 am to 5:00 pm (EDT), Alexandria, VA

    April 30, 2019 – European biotech patent law update (D Young & Co) – 4:00 am, 7:00 am, and 12:00 pm (EDT)

    April 30, 2019 – "Inventive Step for Computer Implemented Inventions at the EPO" (J A Kemp) – 3:30 to 4:30 pm GMT (Greenwich Mean Time)

    April 30, 2019 – "Patent Infringement After Duncan Parking Technologies — Doctrine of Equivalents, Too-Narrow Claim Construction, and Prosecution Impact on Litigation Outcomes" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 2, 2019 – "Patent Inventorship: Best Practices for Determination and Correction — Distinguishing Between Inventor and Contributor; Navigating Joint Inventorship, Disclosure of Ownership, Real Party in Interest" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 7-9, 2019 – Patent Fundamentals Bootcamp 2019: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – Chicago, IL

    May 10, 2019 – "ITC Practice—What Every IP Attorney and In-House Counsel Should Know" (John Marshall Law School Center for Intellectual Property, Information & Privacy Law) – 9:00 am to 4:30 pm, Chicago, IL

    May 16-17, 2019 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY

    June 12-14, 2019 – Patent Fundamentals Bootcamp 2019: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – Chicago, IL

    July 17-19, 2019 – Patent Fundamentals Bootcamp 2019: An Introduction to Patent Drafting, Prosecution, and Litigation (Practising Law Institute) – San Francisco, CA

  • PLI #1Practising Law Institute (PLI) will be holding its Patent Fundamentals Bootcamp 2019: An Introduction to Patent Drafting, Prosecution, and Litigation on May 7-9, 2019 in Chicago, IL, on June 12-14, 2019 in New York, NY, and on July 17-19, 2019 in San Francisco, CA.  The three-day program features lectures each morning followed by clinic sessions in the afternoon where classroom problems and solutions will be furnished.  Both the lectures and clinics follow the patent application process — from invention disclosure and patent preparation (Day 1), through prosecution, issuance and beyond (Day 2) to litigation/claim analysis (Day 3).  Attendees will:

    • Learn how to prepare a patent application that satisfies the statutory requirements for patentability and distinctly claims the subject matter that the applicant regards as the invention with an eye towards successful prosecution and enforcement;
    • Understand how to prosecute an application to obtain allowance of an enforceable patent;
    • Learn how to interview an Examiner;
    • Discover effective uses of reissues, supplemental examination procedures, reexamination, inter partes review, post-grant review, and other post-issuance proceedings;
    • Determine best practices to anticipate patent litigation issues during the patent prosecution process;
    • Get helpful approaches on patent opinion drafting; and
    • Learn how to prepare infringement/invalidity claim charts for litigation.

    PLI faculty will offer presentations on the following topics:

    • Taking a Patent Invention Disclosure
    • Preparation of a Patent Application
    • The Basics of Patent Claim Drafting
    • Clinic I: Patent Claim Drafting
    • Review of Patent Model Claims
    • An Overview of Patent Prosecution
    • Conducting the Examiner Interview
    • Clinic II: Patent Amendment Writing
    • Patent Prosecutor Ethics
    • Patent Litigation Issues
    • Clinic III: Preparing a Patent Claim Chart
    • Patent Claim Chart Review

    A program schedule and list of speakers for each of the locations can be found here.  Patent Docs author Kevin Noonan will be serving as Chicago co-chair and Patent Docs author Donald Zuhn will be presenting on day 1 at the Chicago seminar.

    The registration fee for the conference is $2,195.  Those interested in registering for the conference can do so at the PLI website.

  • JMLSThe John Marshall Law School Center for Intellectual Property, Information & Privacy Law will be hosting an IP Executive Seminar on "ITC Practice—What Every IP Attorney and In-House Counsel Should Know" from 9:00 am to 4:30 pm on May 10, 2019 in Chicago, IL.  The program, which will be presented by Theodore R. Essex of Hogan Lovells, who served for a decade as a U.S. International Trade Commission (ITC) judge, will consist of two sessions:

    • Session I — Covering the ITC's role in adjudication and enforcement of IP rights; Section 337 of the Tariff Act of 1930 and important amendments relating to IP matters; the organization of the ITC, including Commissioners, Administrative Law Judges, and the Office of Unfair Import Investigations; litigation at the ITC — from institution of an investigation to post-hearing phases.
    • Session II — Covering importation, domestic industry, and injury; remedies and the role of U.S. Customs; and key cases from the ITC and U.S. Court of Appeals for the Federal Circuit.

    Additional information about the program can be found here.  Those interested in registering for the conference online can do so here; the registration fee is $295 (general admission) and JMLS students, staff, and faculty can apply for free registration.

  • By Kevin E. Noonan —

    GENRising drug prices is an issue that everyone from the President to both Houses of Congress (Democrats and Republicans), Wall Street, and Main Street can agree must be alleviated, and perhaps the most expensive drugs are those that treat cancer.  This reality is a combination of the severity of the disease and the nature of the drugs, which are generally biologic drugs characterized by structural complexity, production difficulties, and high cost of regulatory approval.  As reported in Genetic Engineering News, the trend of increasing drug prices continued in 2018 among most of the top ten highest selling cancer drugs currently on the market.

    The basis for the information disclosed in GEN is a report from IQVIA™ Institute for Human Data Science entitled Global Oncology Drug Trends 2018, which showed that cancer treatment costs average over $150,000 on 2017 with total spend in the U.S. in these drugs of almost $50 billion (compared with a total of $60 billion for the rest of the world).  The situation may get even worse, with cancer drug prices expected to double again by 2022 in the U.S. and there being an equivalent percentage rise (10-13% annually) in the rest of the world.

    Details of these drugs are provided in the table below.

    TableNote: 2018 Sales and 2017 Sales are in billions.

  • By Donald Zuhn —

    ColoradoLast week, in United Cannabis Corp. v. Pure Hemp Collective Inc., District Judge William J. Martinez of the U.S. District Court for the District of Colorado issued an order denying a motion for partial summary judgment filed by Defendant Pure Hemp Collective Inc., finding that Pure Hemp was not entitled to summary judgment on the record.  Pure Hemp had filed an Early Motion for Partial Summary Judgement, arguing that the asserted claims of U.S. Patent No. 9,730,911, which is owned by United Cannabis Corp. ("UCANN"), were invalid under 35 U.S.C. § 101 (claims 10, 12, 14, 20–22, 25, 27, 28, 31, and 33 of the '911 patent) or 35 U.S.C. § 112(e) (claim 31).

    UCANN had initiated the dispute between the parties by filing a complaint against Pure Hemp for infringement of claims 10, 12, 14, 20–22, 25, 27, 28, 31, and 33 of the '911 patent.  Pure Hemp responded by filing its motion for partial summary judgment, contending that all of the asserted claims were invalid.

    The '911 patent, which is entitled "Cannabis extracts and methods of preparing and using same," is directed to liquid cannabinoid formulations.  Claims 10, 20, and 25 (the independent claims asserted in UCANN's complaint) recite:

    10.  A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids is cannabidiol (CBD).

    20.  A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are THC [tetrahydrocannabinol] and CBD.

    25.  A liquid cannabinoid formulation, wherein at least 95% of the total cannabinoids are CBD, cannabinol (CBN) and THC.

    Asserted claim 31 also recites:

    31.  The formulation of any one of the proceeding claims, wherein the formulation is infused in a medium chain triglyceride (MCT).

    Judge Martinez began his Order by describing the two-part patent eligibility inquiry set forth by the Supreme Court in Alice Corp. Pty. v. CLS Bank Int'l, 573 U.S. 208, 216 (2014):

    "[D]istinguishing patents that claim laws of nature, natural phenomena, and abstract ideas from those that claim patent-eligible applications of those concepts" first requires a court to "determine whether the claims at issue are directed to one of those patent-ineligible concepts."  Id. at 217.  If the answer is no, the inquiry ends; but if the answer is yes, a court must then determine whether the claims in question nonetheless offer "an inventive concept—i.e., an element or combination of elements that is sufficient to ensure that the patent in practice amounts to significantly more than a patent upon the ineligible concept itself."  Id. at 217–18 (internal quotation marks omitted; alterations incorporated).

    Judge Martinez then "summarize[ed] certain Supreme Court and Federal Circuit decisions in which those courts have examined questions of patentability in roughly similar contexts," including Funk Brothers Seed Co. v. Kalo Inoculant Co., 333 U.S. 127 (1948); Diamond v. Chakrabarty, 447 U.S. 303 (1980); Mayo Collaborative Services v. Prometheus Laboratories, Inc., 566 U.S. 66 (2012); and Ariosa Diagnostics, Inc. v. Sequenom, Inc., 788 F.3d 1371 (Fed. Cir. 2015).  After providing summaries of the above cases, Judge Martinez offered his comments on the Alice test, stating that:

    [T]he proper application of the Supreme Court's Alice standard is an evolving and sometimes hazy area of law.  Deciding whether a patent claim is "directed to" a law of nature is not as straightforward as the Supreme Court makes it sound in Alice itself.  Moreover, the Federal Circuit itself has remarked on the difficulty, at times, of distinguishing the first Alice inquiry from the second, see, e.g., Elec. Power Grp., LLC v. Alstom S.A., 830 F.3d 1350, 1353 (Fed. Cir. 2016); or distinguishing the two Alice inquiries (comprising a patentability analysis rooted in 35 U.S.C. § 101) from other common inquiries such as anticipation and obviousness (which are rooted in 35 U.S.C. §§ 102–03), see, e.g., Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc., 827 F.3d 1042, 1052 & n.2 (Fed. Cir. 2016).

    However, after applying the Alice test to the asserted claims, Judge Martinez determined that "[d]espite the potential ambiguities [of the Alice test], the Court is convinced under the current state of the case law that the challenged claims of the 911 Patent are not directed at unpatentable subject matter."  With respect to the first Alice inquiry, Pure Hemp had argued that the asserted claims are "directed to" the patent ineligible natural phenomenon of the specified chemical compounds (cannabinoids, terpenes, and flavonoids).  UCANN had countered that "the claims are not directed to laws of nature or natural phenomena because they claim human-modified liquid formulations that require converting solid cannabinoids into a different state with markedly different physiological characteristics" (citation omitted).

    The Court was persuaded by UCANN's argument that the claims are directed to human-modified liquid formulations, and did not feel the need to address the second part of UCANN's argument (i.e., that the claimed liquid formulations had been converted into a different state having markedly different physiological effects).  Judge Martinez explained that:

    Pure Hemp has failed to establish beyond genuine dispute that a liquefied version of cannabinoids and related chemicals at the concentrations specified in the 911 Patent is anything like a natural phenomenon.  It may be true, as Pure Hemp insists, that cannabinoids in nature can take the form of a resin; that a resin can be highly viscous; that a highly viscous substance may at times be considered a liquid; and therefore it is logically possible that cannabinoids in nature might appear in a form that could, in some sense, be deemed a "liquid."  . . .  Even accepting as much, the 911 Patent specifies threshold concentrations of cannabinoids and related chemicals.  Pure Hemp nowhere claims that these precise concentrations, or anything close to them, occur in liquid form in nature.  Accordingly, UCANN's claims are not restatements of "the handiwork of nature," Funk Brothers, 333 U.S. at 131, "but [UCANN's] own [handiwork]," Chakrabarty, 447 U.S. at 310.

    While noting that "the Court sees reason to question whether the 911 Patent claims anything novel, useful, or nonobvious," with respect to the Alice inquiry, the Court determined that "the 911 Patent is not 'directed to' an unpatentable law of nature, a natural phenomenon, or an abstract idea," but "is instead 'directed to' a non-naturally occurring delivery method of naturally occurring chemicals in (as far as the record reveals) non-naturally occurring proportions and concentrations."  Finding that the asserted claims did not fail at step one of the Alice inquiry, the Court determined that it did not need to address step two.

    As for claim 31, Pure Hemp argued that this claim was invalid for depending from a multiple dependent claim when claim 31 is itself a multiple dependent claim (i.e., claim 31 depends from "any preceding claim" — following UCANN's correction of the claim — and claim 9 depends from claim 1 or 5, and claim 24 depends from claim 16 or 20).  Judge Martinez noted, however, that UCANN had disclaimed claim 9 and 24, and cited Guinn v. Kopf, 96 F.3d 1419, 1422 (Fed. Cir. 1996), for the proposition that "[a] statutory disclaimer under 35 U.S.C. § 253 has the effect of canceling the claims from the patent and the patent is viewed as though the disclaimed claims had never existed in the patent."  While noting that "[o]ne would expect that this would end the argument as to Claim 31," the Order points out that Pure Hemp insisted in its reply brief that the Court could still declare claim 31 to be invalid for depending from multiple dependent claims, even though those multiple dependent claims are now deemed to be nonexistent.  To support its argument, Pure Hemp relied on Rembrandt Wireless Technologies, LP v. Samsung Electronics Co., 853 F.3d 1370 (sFed. Cir. 2017), in which the patentee had disclaimed one of two claims in order to seek damages that would have been otherwise prohibited by a failure to mark its products.  Pure Hemp argued that the same public notice concerns raised in Rembrandt Wireless undergird the requirements of 35 U.S.C. § 112(e) with respect to multiple dependencies, and therefore contended that there must be "clear public notice" of invalidity.  Judge Martinez, however, noted that Pure Hemp's argument was circular, since "Claim 31 is not invalid anymore, at least not on account of the multiple dependency problem that existed before UCANN's disclaimer," finding that "there is neither a good reason nor a statutory basis to declare Claim 31 invalid, even though it previously depended on multiple dependent claims."

    Rejecting both of Pure Hemp's invalidity arguments, the District Court denied Pure Hemp's Early Motion for Partial Summary Judgment.

    United Cannabis Corp. v. Pure Hemp Collective Inc. (D. Colo. 2019)
    Order Denying Defendant's Early Motion for Partial Summary Judgment by District Judge Martinez

  • By Kevin E. Noonan —

    Washington - Capitol #3A great deal of faith has recently been given to Congress by the patent community, spurred by efforts to solve the conundrums in patent law created by several recent Supreme Court decisions (and aided and abetted by the U.S. Patent and Trademark Office, district courts, and the Federal Circuit).  Last week, Congress provided ample evidence that a degree of caution (if not a grain of salt) should arise regarding anything Congress does with the introduction by Senator Bill Cassidy (R-LA) (along with several "co-conspirators") of three bills ostensibly aimed at "solving" the problem of "excessively high" prescription drug prices.  A gastroenterologist before standing for elective office, Senator Cassidy's sympathies (if not prejudices) are both evident and understandable.  But as policies, they are ill conceived and unlikely to have anything more than a cosmetic effect.

    The bill proposing the most extensive changes, entitled "Reforming Evergreening and Manipulation that Extends Drug Years Act'' (or the ''REMEDY Act,'' showing that clever acronyms for legislation is a trope that has outlived whatever cleverness it ever had), would be better called the "Launch at Risk Act."  The changes proposed in Section 505(c)(3)(C) of the Food, Drug, and Cosmetic Act (codified at 21 U.S.C. 355) read as follows (in italics):

    If the applicant made a certification described in clause (iv) of subsection (b)(2)(A) [colloquially known as a "Paragraph IV Certification"], the approval shall be made effective immediately unless, in the case of a certification with respect to a patent that claims a drug substance (and not in the case of a certification with respect to a patent that claims a drug product or method of use for a drug, except that, in the case of a patent that claims a drug substance and a drug product or method of use, this subparagraph shall apply, but only to the extent the  patent claims a drug substance), before the expiration of 45 days after the date on which the notice described in subsection (b)(3) is received, an action is brought for infringement of the patent that is the subject of the certification and for which information was submitted to the Secretary under paragraph (2) or subsection (b)(1) before the date on which the application (excluding an amendment or supplement to the application) was submitted.

    Also proposed is amendment to Section 505(j)(5)(B)(iii) of the FDCA:

    (iii)  If the applicant made a certification described in subclause (IV) of paragraph (2)(A)(vii), the approval shall be made effective immediately unless, in the case of a certification with respect to a patent that claims a drug substance (and not in the case of a certification with respect to a patent that claims a drug product or method of use for a drug, except that, in the case of a patent that claims a drug substance and a drug product or method of use, this clause shall apply, but only to the extent the patent claims a drug substance), before the expiration of 45 days after the date on which the notice described in paragraph (2)(B) is received, an action is brought for infringement of the patent that is the subject of the certification and for which information was submitted to the Secretary under subsection (b)(1) or (c)(2) before the date on which the application (excluding an amendment or supplement to the application), which the Secretary later determines to be substantially complete, was submitted.

    If enacted into law, a patent-holding, branded drug maker would only be able to have the benefit of the 30-month stay enshrined in these provisions of the Hatch-Waxman Act for patents claiming a drug substance itself, but not formulations or methods of treatment using a patented, branded drug under an NDA.  An ANDA applicant could have FDA approve its generic drug and to enter the marketplace with no further ado.

    Of course, this is the classic "launch at risk" scenario, and the generic drug maker would risk not only an injunction preventing marketing of its generic drug until any patent to formulation or method of treatment has expired, but also treble damages for willful infringement.  This scenario may be much less attractive to actual generic drug companies than Senator Cassidy and his co-sponsors believe it will be.

    The bill would also amend Section 505(j)(7)(A) by adding the following language:

    (iv) In the case of a listed drug for which the list under clause (i) includes a patent that claims the drug or a use for such drug, and where the Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office has cancelled any claim of the patent relating to such drug or such use pursuant to a determination by the Patent Trial and Appeal Board in an inter partes review conducted under chapter 31 of title 35, United States Code, or a post-grant review conducted under chapter 32 of that title, and any such cancellation, if appealed, has been upheld upon appeal, the holder of the applicable approved application shall notify the Secretary of such cancellation, and the revisions required under clause (iii) shall include striking the patent from the list with respect to such drug.

    And finally the bill would amend Section 505(j)(5)(B)(iv)(I) regarding the 180-day exclusivity period:

    This subclause shall apply even if a patent is stricken from the list under paragraph (7)(A), pursuant to the second sentence of clause (iii) of such paragraph, provided that, at the time that the first applicant submitted an application under this subsection containing a certification described in paragraph (2)(A)(vii)(IV), the patent that was the subject of such certification was included in such list with respect to the listed drug.

    These revisions are cosmetic insofar as they merely bring the statute into conformity with the changes proposed for Sections 505(c)(3)(C) and 505(j)(5)(B)(iii) and thus bear little further discussion.

    Two other bills have been formally introduced by Senator Cassidy's colleagues joined by him.  One, introduced by Senator Cory Gardner (R-CO) and Jeanne Shaheen (D-NH) and Senator Cassidy, is entitled "Ensuring Timely Access to Generics Act," and proposes changes to Section 505(q)(1) in order enable the Secretary to reject a citizen petition directed merely to delaying generic drug entry:

    (E) Denial based on intent to delay

    (i) IN GENERAL.—If the Secretary determines that a petition or a supplement to the petition was submitted with the primary purpose of delaying the approval of an application and the petition does not on its face raise valid scientific or regulatory issues, the Secretary may deny the petition at any point based on such determination. The Secretary may issue guidance to describe the factors that will be used to determine under this subparagraph whether a petition is submitted with the primary purpose of delaying the approval of an application.

    (ii) FACTORS.—In determining whether a petition was submitted with the primary purpose of delaying the approval of an application, the Secretary shall consider—

    (I) whether it appears, based on the date that relevant information relied upon in the petition became known to the petitioner (or reasonably should have been known to the petitioner), as certified by the petitioner in accordance with subparagraph (H), that the petitioner has taken an unreasonable length of time to submit the petition;

    (II) whether the petitioner has submitted multiple or serial petitions raising issues that reasonably could have been known to the petitioner at the time of submission of the earlier petition or petitions;

    (III) whether the petition was submitted close in time to a known, first date upon which an application under subsection (b)(2) of this section or section 351(k) of the Public Health Service Act could be approved;

    (IV) whether the petition was submitted without any data or information in support of the scientific positions set forth in the petition;

    (V) whether the petition raises the same or substantially similar issues as a prior petition to which the Secretary has responded substantively already, particularly if the subsequent submission follows the earlier response closely in time;

    (VI) whether the petition concerns standards for approval of a drug for which the Secretary has provided an opportunity for public input, such as draft or final product-specific guidance applicable petitioner has not provided comment other than through the petition;

    (VII) whether the petition requests that other applicants meet standards for testing, data, or labeling for a drug that are more onerous or rigorous than the standards applicable to, as applicable, the listed drug, reference product, or petitioner's version of the same drug;

    (VIII) the history of the petitioner with the Food and Drug Administration, such as whether the petitioner has a history of submitting petitions that the Secretary has determined were submitted with the primary purpose of delay; and

    (IX) other relevant considerations, as the Secretary may describe in guidance.''; and

    (C) by adding at the end the following:

    (iii) PUBLIC AVAILABILITY.—The Secretary shall publish on the internet  website of the Food and Drug Administration a list of any petitions that the Secretary determines were submitted for the primary purpose of delaying the approval of an application.

    (iv) REFERRAL TO THE FEDERAL TRADE COMMISSION.—The Secretary shall establish procedures for referring to the Federal Trade Commission any petition or supplement to a petition that the Secretary determines was submitted with the primary purpose of delaying approval of an application. Such procedures shall include notification to the petitioner and an opportunity for the petitioner to respond to the Secretary prior to referral to the Federal Trade Commission.''; and

    (2) by adding at the end the following:

    (J) TIMELINE FOR SUBMITTING PETITIONS.—The Secretary may establish a time period after the relevant information relied upon in a petition became known to the petitioner (or reasonably should have been known to a petitioner), as certified by the petitioner in accordance with subparagraph (H), and any petition that is submitted after such time period has passed shall be summarily denied.

    The bill tracks a draft Guidance released by FDA last year representing the agency's attempt to address the perceived problem with frivolous citizen petitions.  The significance and effect of such changes may depend on how much one considers branded drug makers are filing frivolous citizen petitions (or that they are having substantive effects) and whether the changes would pass constitutional muster on free speech and right to petition the Federal government for redress of grievances grounds.

    The other bill, introduced by Senator Tina Smith (D-MN), is entitled the ''Protecting Access to Biosimilars Act" and is directed to changes in the BPCIA under Section 351(k)(7) of the Public Health Service Act (codified at (42 U.S.C. § 262(k)(7)).  The bill proposes these changes to the statutory language:

    (D) DEEMED LICENSES.—

    (i) NO ADDITIONAL EXCLUSIVITY THROUGH DEEMING.—An approved application that is deemed to be a license for a biological product under this section pursuant to section 7002(e)(4) of the Biologics Price Competition and Innovation Act of 2009 shall not be treated as having been first licensed under subsection (a) for purposes of subparagraphs (A) and (B).

    (ii) LIMITATION ON EXCLUSIVITY APPLIES TO ANY REFERENCE PRODUCT.—

    Subparagraph (C) shall apply to any reference product, without regard to whether—

    (I) such product was first licensed under subsection (a); or

    (II) the approved application for such product was deemed to be a license for a biological product as described in clause (i).

    Paradoxically this bill has the highest chance of passage, according to Ryan Davis at IP Law 360 (subscription required) as being directed to insulin, which has been licensed under the FDCA since the 1930's but is slated to come under the auspices of the BPCIA in 2020.  According to Mr. Davis, this bill is intended to prevent this change from bestowing on a biologic drug-classified insulins a 12-year exclusivity under the BPCIA.  As with the Timely Act, the effect enactment of this bill into law would have depends on the magnitude of the problem that prompted its introduction.

    As has been said in other contexts, political posturing is in vogue and particularly posturing regarding prescription drug prices.  It is unclear whether any of these proposed changes in the law will remedy any real problems that underlie high drug prices.  Bills like these only address part of those problems but at the cost of addressing systemic issues with drug pricing not as amenable to quick or simple changes in existing law.

  • CalendarApril 22, 2019 – "A conversation with Shawn Springs" (U.S. Patent and Trademark Office) – 11:00 am to noon, Alexandria, VA

    April 29-30, 2019 – Paragraph IV Disputes master symposium (American Conference Institute) – New York, NY

    April 23, 2019 – "Recent Developments in Biopharma Patent Law" (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:30 pm, San Diego, CA (Hyatt Regency La Jolla at Aventine)

    April 23, 2019 – "From Boston & Beyond: Local and Global Implications of Recent Changes in Patent Practice" (Federal Circuit Bar Association) – 1:00 pm to 4:30 pm (EST), Suffolk University School of Law, Boston, MA

    April 23, 2019 – "Drafting Patent Applications for AI Systems — Overcoming Patent Eligibility, Inventorship, and Enablement Challenges and Avoiding Rejections" (Strafford) – 1:00 to 2:30 pm (EDT)

    April 24, 2019 – "Recent Developments in Biopharma Patent Law" (McDonnell Boehnen Hulbert & Berghoff LLP and Patent Docs) – 9:30 am to 1:30 pm, Burlingame, CA (Hyatt Regency San Francisco Airport)

    April 25, 2019 – "Drug Substance Patents: FDA Guidance, Protecting Composition-of-Matter Patents, Drafting Solid Form Claims" (Strafford) – 1:00 to 2:30 pm (EDT)

    April 25, 2019 – "IPR Estoppel One Year After SAS" (Intellectual Property Owners Association) – 2:00 to 3:00 pm (ET).

    April 29, 2019 – USPTO World Intellectual Property Day Celebration (U.S. Patent and Trademark Office, World Intellectual Property Organization, American Intellectual Property Law Association, U.S. Chamber of Commerce Global IP Center, International Trademark Association, American Bar Association's Section on Intellectual Property Law, and Intellectual Property Owners Association) – 4:00 to 6:30 pm, Rayburn House Office Building Foyer, Washington, DC

    April 30, 2019 – Customer partnership meeting of TC 3600 and TC 3700 (U.S. Patent and Trademark Office and American Intellectual Property Law Association) – 8:45 am to 5:00 pm (EDT), Alexandria, VA

    April 30, 2019 – European biotech patent law update (D Young & Co) – 4:00 am, 7:00 am, and 12:00 pm (EDT)

    April 30, 2019 – "Inventive Step for Computer Implemented Inventions at the EPO" (J A Kemp) – 3:30 to 4:30 pm GMT (Greenwich Mean Time)

    April 30, 2019 – "Patent Infringement After Duncan Parking Technologies — Doctrine of Equivalents, Too-Narrow Claim Construction, and Prosecution Impact on Litigation Outcomes" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 2, 2019 – "Patent Inventorship: Best Practices for Determination and Correction — Distinguishing Between Inventor and Contributor; Navigating Joint Inventorship, Disclosure of Ownership, Real Party in Interest" (Strafford) – 1:00 to 2:30 pm (EDT)

    May 16-17, 2019 – Advanced Summit on Life Sciences Patents (American Conference Institute) – New York, NY